Bristol Myers stock rose over 4% after JPMorgan and William Blair endorsed the company's decision to expand enrollment in the ADEPT-2 Phase 3 Alzheimer psychosis trial. A monitoring committee recommended continuing the study after interim review, drawing renewed retail optimism and speculation of upside into March.